Protagonist Therapeutics (PTGX) Stock News — Real-Time Coverage

Latest Protagonist Therapeutics (PTGX) stock news: "Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today" (Benzinga). Real-time PTGX headlines aggregated from WSJ, Bloomberg, NYT, FT, and Google News. Free and ad-free.

Loading analysis...

Loading Truth Social...

Loading live updates...

Recent PTGX News Headlines

Latest news coverage for PTGX aggregated from WSJ, Bloomberg, The New York Times, Financial Times, and Google News. Real-time updates, free and ad-free.

  1. Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth TodayBenzinga · 2026-09-28
  2. Protagonist Therapeutics Insider Sold Shares Worth $18,240,568, According to a Recent SEC FilingYahoo Finance · 2026-09-11
  3. Protagonist Therapeutics at Cantor conference: cash, launches and pipelineInvesting.com · 2026-09-10
  4. Protagonist Therapeutics Announces $300 Million Share Repurchase ProgramYahoo Finance · 2026-09-08
  5. Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster StatusYahoo Finance · 2026-09-06
  6. MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?Yahoo Finance · 2026-09-04
  7. Protagonist Therapeutics stock rating maintained at Buy by Clear StreetInvesting.com · 2026-08-31
  8. Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strengthInvesting.com · 2026-08-31
  9. Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform By Investing.comInvesting.com · 2026-08-31
  10. Wolfe Research reiterates Protagonist Therapeutics stock rating at outperformInvesting.com · 2026-08-31
  11. Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow (NASDAQ:PTGX) 2026-08-31Seeking Alpha · 2026-08-31
  12. J&J granted China nod for oral psoriasis pill developed with ProtagonistSeeking Alpha · 2026-08-28
  13. Protagonist Therapeutics CEO Dinesh Patel sells $14.9m in stockInvesting.com · 2026-08-12
  14. Protagonist Therapeutics: 'Strong Buy' ICOTYDE FDA Approval And PN-881 Advancement (PTGX)Seeking Alpha · 2026-08-12
  15. Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) StockYahoo Finance · 2026-08-07
Settings
Appearance
Card Style
Language
Live View Style
News Sources
AI Summary for Long Articles
Content Filter
News Aggregation
Recency
Trump Truth Social
About
Version 2.6.1
Data Source r/wallstreetbets
AI Engine ChatGPT/Gemini/Claude
MCP Server https://mcp.sellthenews.org/mcp
Contact Us [email protected]